3

Navid Alipour, a co-founder and managing partner of San Diego's Analytics Ventures, said his firm's portfolio company CureMatch is taking a direct-to-consumer approach, in which cancer patients pay CureMatch to recommend the top three combinations of chemotherapy drugs for each patient's cancer. The recommendations, based on information in a patient's own medical record, is intended to help cancer specialists choose a treatment regimen. CureMatch says it uses supercomputer processing to sort through millions of possible three-drug combinations, assessing each combination for factors like unwanted drug-drug interactions, and correlating genomic data to rank the best drug combinations for a specific patient. CureMetrix, another company in Analytics Ventures' portfolio, uses machine learning to analyze mammography images for breast cancer--and must still get FDA approval before it can be used in the United States, Alipour said. "It will be a [software as a service] model," Alipour said.